Items tagged with Drug-resistant TB
Shorter regimen for resistant TB could save $740 million a year (post)
17 December 2022: An analysis yesterday by researchers with the TB Alliance, Stop TB Partnership, World Health Organization (WHO), and other groups estimates that the recently approved BPaLM/BPaL treatment regimen for drug-resistant tuberculosis (DR-TB) could save governments up to $740 million a year, enough to supply more than 400,000 people with almost a year's worth of DR-TB treatment.
In-depth: New resistance tests set to improve TB treatment (post)
Some strains of the TB bacterium have mutated to become resistant to some of the drugs commonly used to treat TB. Accordingly, one of the first questions to ask when someone has TB is which drugs will be effective in fighting that person’s TB. Unfortunately, quick answers to this question are not always available. As a consequence, people are at times treated with drugs that won’t work for their particular strain of TB. What’s worse, these drugs often have significant side effects.
RESIST-TB November 2022 newsletter (post)
RESIST-TB released its November 2022 newsletter with the latest research publications on drug-resistant TB.
Failure of TB treatment linked to bacterial resilience (post)
Boston, MA, December 8, 2022 – Researchers have discovered a new form of altered drug susceptibility—dubbed antibiotic resilience—that enables Mycobacterium tuberculosis (Mtb) to survive antibiotic treatment. The study, led by Harvard T.H. Chan School of Public Health, could help inform future therapeutics and reduce treatment failure in tuberculosis patients.
Undernutrition linked to increased mortality in multidrug-resistant TB (post)
Patients with multidrug-resistant tuberculosis with a body mass index of less than 18.5kg/m2 had a 2.8-times higher odds of death.
RESIST-TB December 2022 newsletter (post)
RESIST-TB released its December 2022 newsletter with the latest research publications on drug-resistant TB.
India: Molbio Diagnostics launches test to expand its multidrug-resistant TB portfolio (post)
Truenat MTB-INH is also expected to play a major role internationally, in high TB burden countries as well as countries that already have a policy in place for INH testing on all TB-positive samples, it claimed.
Study shows FDA-approved TB regimen may not work against the deadliest form of TB due to multidrug-resistant strains (post)
Findings from a Johns Hopkins Children's Center study in animal models show that a U.S. Food and Drug Administration (FDA)-approved antibiotic regimen for multidrug-resistant (MDR) tuberculosis (TB) may not work for TB meningitis. Studies in a small number of people also provide evidence that a new combination of drugs is needed to develop effective treatments for TB meningitis due to MDR strains.
Final hearing in TB drug patent case ends, verdict likely in a month (post)
New Delhi: The Indian Patent Office had held its final hearing on a challenge filed by two tuberculosis survivors to prevent the Indian arm of drugmaker Johnson & Johnson from extending its patent on bedaquiline, used against drug-resistant TB, beyond the primary patent’s expiry in July.
RESIST-TB February 2023 newsletter (post)
RESIST-TB released its February 2023 newsletter with the latest research publications on drug-resistant TB.
Page 78 of 117 · Total posts: 0
←First 77 78 79 Last→